2023
Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients
Kwan J, Arbune A, Henry M, Hu R, Wei W, Nguyen V, Lee S, Lopez-Mattei J, Guha A, Huber S, Bader A, Meadows J, Sinusas A, Mojibian H, Peters D, Lustberg M, Hull S, Baldassarre L. Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients. PLOS ONE 2023, 18: e0286364. PMID: 37252927, PMCID: PMC10228774, DOI: 10.1371/journal.pone.0286364.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSystolic heart failureCardiovascular outcomesCancer patientsHeart failureValvular diseaseStrain abnormalitiesLeft ventricular ejection fraction reductionCancer treatment-related cardiotoxicityCardiovascular magnetic resonance findingsVentricular ejection fraction reductionYale-New Haven HospitalEjection fraction reductionTreatment-related cardiotoxicityAdverse cardiovascular outcomesClinical risk factorsNormal LV functionGlobal longitudinal strainIschemic heart diseaseMagnetic resonance findingsRisk regression modelsNew Haven HospitalSubclinical cardiotoxicityDiastolic dysfunctionStatin use
2021
Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience
Batra A, Patel B, Addison D, Baldassarre LA, Desai N, Weintraub N, Deswal A, Hussain Z, Brown SA, Ganatra S, Agarwala V, Parikh PM, Fradley M, Ghosh A, Guha A. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart 2021, 8: e001849. PMID: 34952868, PMCID: PMC8710909, DOI: 10.1136/openhrt-2021-001849.Peer-Reviewed Original ResearchConceptsCardiovascular adverse eventsAdverse Event Reporting SystemCombination therapyAntimicrotubular agentsVinca alkaloidsAdverse eventsDrug Administration Adverse Event Reporting SystemRoutine cardiovascular assessmentCardiovascular safety profilePolytomous logistic regressionEvent Reporting SystemAgent therapyCombination chemotherapyHeart failureRegistry experienceSafety profileCardiovascular assessmentHigh burdenInhibitor combinationsChemotherapeutic agentsTaxanesTherapyLogistic regressionMonotherapyReporting systemLeft ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity
Higgins AY, Arbune A, Soufer A, Ragheb E, Kwan JM, Lamy J, Henry M, Cuomo JR, Charifa A, Gallegos C, Hull S, Coviello JS, Bader AS, Peters DC, Huber S, Mojibian HR, Sinusas AJ, Kluger H, Baldassarre LA. Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity. PLOS ONE 2021, 16: e0246764. PMID: 33606757, PMCID: PMC7895343, DOI: 10.1371/journal.pone.0246764.Peer-Reviewed Original ResearchConceptsGlobal longitudinal strainImmune checkpoint inhibitorsLate gadolinium enhancementRecovery of LVEFLake Louise criteriaCheckpoint inhibitorsNormal LVEFAverage global longitudinal strainPresence of LGEAbnormal global longitudinal strainCardiac magnetic resonance imagingCorrect clinical contextEvaluation of myocarditisLeft ventricular dysfunctionVentricular ejection fractionDiagnosis of myocarditisLeft ventricular strainCardiac magnetic resonanceLeft ventricular myocardial strainOvert left ventricular dysfunctionVentricular myocardial strainMagnetic resonance imagingAtrial strainVentricular dysfunctionVentricular strain
2020
Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils
Baldassarre LA, Yang EH, Cheng RK, DeCara JM, Dent S, Liu JE, Rudski LG, Strom JB, Thavendiranathan P, Barac A, Zaha VG, Bucciarelli-Ducci C, Ellahham S, Deswal A, Lenneman C, Villarraga HR, Blaes AH, Ismail-Khan R, Ky B, Leja MJ, Scherrer-Crosbie M. Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. Journal Of The National Cancer Institute 2020, 113: 513-522. PMID: 33179744, PMCID: PMC7717327, DOI: 10.1093/jnci/djaa177.Peer-Reviewed Original ResearchMeSH KeywordsCardiotoxicityCardiovascular DiseasesCOVID-19Diagnostic ImagingExpert TestimonyHumansNeoplasmsSARS-CoV-2ConceptsCardio-OncologyCardiovascular careCOVID-19Cardio-oncology patientsPrior cancer historyExpert consensus statementCoronavirus disease 2019 (COVID-19) pandemicExpert consensus documentRisk of infectionDisease 2019 pandemicCardiotoxicity surveillanceCardiovascular complicationsPericardial involvementLethal complicationCardiac dysfunctionOncology patientsRisk of exposureCancer historyCancer patientsCardiovascular diseaseConsensus statementAmerican CollegeCardiovascular treatmentConsensus documentPatientsOpportunities for improved cardiovascular disease prevention in oncology patients.
Bravo-Jaimes K, Marcellon R, Varanitskaya L, Kim PY, Iliescu C, Gilchrist SC, Baldassarre LA, Manisty C, Ghosh AK, Guha A, Lopez-Mattei JC. Opportunities for improved cardiovascular disease prevention in oncology patients. Current Opinion In Cardiology 2020, 35: 531-537. PMID: 32649353, DOI: 10.1097/hco.0000000000000767.Peer-Reviewed Original ResearchConceptsCardiovascular disease preventionCancer patientsDisease preventionCardiovascular disease prevention guidelinesCardiac risk factor modificationCancer treatmentCardiometabolic disease managementDisease prevention guidelinesCardiovascular risk factorsHigh cardiovascular riskRisk factor modificationAdverse cardiovascular outcomesRisk of cardiotoxicityOngoing clinical trialsNonpharmacologic therapiesCardiovascular eventsCardiovascular outcomesCardiovascular riskOncology patientsCancer survivorsPrevention guidelinesAdverse outcomesFactor modificationCardiorespiratory fitnessRisk factors
2019
Nuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods
Soufer A, Liu C, Henry ML, Baldassarre LA. Nuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods. Journal Of Nuclear Cardiology 2019, 27: 1210-1224. PMID: 30868378, DOI: 10.1007/s12350-019-01671-6.Peer-Reviewed Original ResearchConceptsCardiac toxicityPre-clinical cardiotoxicityCardiac magnetic resonanceNuclear cardiologyCardiovascular outcomesNon-invasive imagingCardiovascular toxicityChemotherapeutic agentsCancer treatmentEarly detectionCardiac imagingCancer therapyCancer therapeuticsCardiologyToxicityMagnetic resonanceTreatmentImagingEchocardiographyPatientsCardiotoxicityTherapyCancerSeverityCare